Dimension Therapeutics Inc (NASDAQ:DMTX) has been given an average rating of “Hold” by the six research firms that are currently covering the company. Four equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $10.00.
Several research firms have recently commented on DMTX. Zacks Investment Research raised Dimension Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research report on Tuesday, April 18th. Cantor Fitzgerald set a $3.00 price target on Dimension Therapeutics and gave the stock a “hold” rating in a research report on Saturday, March 11th. Canaccord Genuity set a $20.00 price target on Dimension Therapeutics and gave the stock a “buy” rating in a research report on Saturday, March 11th. Citigroup Inc lowered Dimension Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $7.00 price target on shares of Dimension Therapeutics in a research report on Thursday, February 2nd.
A number of hedge funds have recently bought and sold shares of DMTX. Turner Investments LLC purchased a new stake in Dimension Therapeutics during the fourth quarter valued at $131,000. Renaissance Technologies LLC purchased a new stake in Dimension Therapeutics during the fourth quarter valued at $236,000. State Street Corp increased its stake in Dimension Therapeutics by 37.2% in the fourth quarter. State Street Corp now owns 186,544 shares of the biotechnology company’s stock valued at $812,000 after buying an additional 50,570 shares during the last quarter. Baker BROS. Advisors LP purchased a new stake in Dimension Therapeutics during the third quarter valued at $10,003,000. Finally, New Leaf Venture Partners L.L.C. purchased a new stake in Dimension Therapeutics during the fourth quarter valued at $8,958,000. Institutional investors and hedge funds own 85.43% of the company’s stock.
Dimension Therapeutics (NASDAQ:DMTX) opened at 1.35 on Friday. The firm has a 50-day moving average price of $1.55 and a 200-day moving average price of $3.16. Dimension Therapeutics has a 12-month low of $1.35 and a 12-month high of $10.47. The company’s market cap is $33.81 million.
Dimension Therapeutics (NASDAQ:DMTX) last released its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.02. The company had revenue of $3.62 million during the quarter. Dimension Therapeutics had a negative return on equity of 50.07% and a negative net margin of 464.39%. On average, equities research analysts forecast that Dimension Therapeutics will post ($2.11) earnings per share for the current fiscal year.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).